Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant

This article was originally published in The Gray Sheet

Executive Summary

European unit sales of coronary stents grew 19% in the third quarter, "driven by the launch of the Multi-Link Tetra," the company reports Oct. 12. The fourth-generation stent was approved for U.S. marketing on Oct. 3 (1"The Gray Sheet" Oct. 9, 2000, p. 16). Overall, stent revenues were $165 mil. worldwide and $111.5 mil. in the U.S. for the three months ended Sept. 30, reflecting declines of 20% and 24%, respectively. U.S. sales of implantable defibrillators, led by the Ventak Prizm, were up 24% to $137.6 mil., while domestic pacemaker sales, led by the Pulsar line, increased 11% to $88.1 mil. Guidant's third-quarter corporate revenue increased 6% to $600.8 mil., and net income advanced 25% to $122.8 mil
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT013990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel